23:27:26 Europe / Stockholm

Prenumeration

2023-08-30 13:30:00

Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profitability. We lower our fair value range but the drastic 43% drop observed yesterday reflects an excessively pessimistic and short-term perspective on the company.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/